OKUR

Onkure Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth 3/10
  • Value 8/10
Onkure Therapeutics sales and earnings growth
OKUR Growth
Neutral
  • Revenue Y/Y 0.00%
  • EPS Y/Y -131.08%
  • FCF Y/Y 6.89%
Onkure Therapeutics gross and profit margin trends
OKUR Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -4874.87%
Onkure Therapeutics net debt vs free cash flow
OKUR Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage -7342.6

Onkure Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks